UK regulator safeguarding medicines and medical devices
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
A comprehensive review links vaping to respiratory and other health harms in children and young people, with warnings about pregnancy exposure. UK officials are urged to extend restrictions to limit flavours and marketing to protect youths while continuing to support smoking cessation for adults.
Nice has approved a weekly insulin to reduce injections from 365 to 52, but MHRA approval is pending. The treatment—Onswik, by Eli Lilly—could improve daily life for patients who rely on carers or face dexterity challenges. NHS readiness hinges on regulatory licensing and clear rollout guidelines.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
Experts from University College London and MHRA have said there is no credible evidence that ethylene oxide–sterilised swabs used in cervical screening endanger patients. The claim on social media about cancer risk has been debunked. Cervical cancer diagnoses in the UK remain around 3,000 annually, and screening uptake has fallen to 66% of eligible women as of 2024.